Zika vaccine candidate shows promise in early human trial
NCT ID NCT06334393
First seen Mar 16, 2026 · Last updated May 14, 2026 · Updated 5 times
Summary
This study tested a new vaccine called VLA1601 to see if it is safe and can protect against the Zika virus, which can cause serious birth defects. The trial involved 150 healthy adults aged 18 to 49 who had never been exposed to similar viruses. Participants received two shots of the vaccine at different dose levels, and researchers monitored side effects and immune responses for several months.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ZIKA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Flourish Research
Chicago, Illinois, 60640, United States
-
Velocity Clinical Research
Sioux City, Iowa, 51106, United States
-
Velocity Clinical Research
Lincoln, Nebraska, 68510, United States
-
Velocity Clinical Research
Omaha, Nebraska, 68134, United States
Conditions
Explore the condition pages connected to this study.